TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06270654

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block
Description: After consent was obtained, patients will be randomised into control group and an intervention group. For patients randomized into the interventional group, bilateral erector spinae plane block will be performed under general anaesthesia in prone position before the operation. An experienced anaesthetist performs this under ultrasound guidance (using curvilinear probe) in a sterile method.~After identifying L3 transverse process, 21G Stimuplex needle will be inserted via in-plane method. Once needle placement is confirmed and aspiration is negative, 20ml of ropivacaine 0.375% with adrenaline 1:200,000 dilution will be given on each side.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Skin infiltration LA
Description: Pre incision of 0.375% ropivacaine 10ml local infiltration will be given to control group
Study: NCT06546371

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulator
Description: Electrical stimulation of the dorsal horn to reduce chronic pain.
Study: NCT04919928

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cochlear Implant and Hearing aid in bimodal solution
Description: Sixty adult participants with bilateral hearing aids (HA) referred for cochlear implantation (CI) will be included in the study. It will be patients who report limited benefit with appropriately fitted HAs in daily speech communication in quiet and in noise. The patients are depending on visual cues for successful communication.~All the referred patients have potential optimal fitted HAs that are no longer sufficient to treat their hearing loss and to improve the daily communication. All the patients will then receive new replacement HAs with the ability to corporate with a CI for one month trial period. One month is considered as a sufficient adaptation period to new replacement HAs according to current clinical practice.~Thirty individuals randomised to receive the intervention with CI to the poorest hearing ear.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bilateral hearing aids
Description: Thirty individuals randomised to the control group will continue use of the new replacement HAs another three months, thus in total of four months of use.
Study: NCT05482360

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PrEP Optimization Interventions
Description: There will be three strategies or bundles of strategies tested determined based on the qualitative information gathered in Aim 1 by stakeholders and are unknown at this time.
Study: NCT06272422

Intervention type: PROCEDURE
Intervention: hip arthroplasty
Description: resurfacing procedures (HRP), THA and Minihip-type neck-preserving total hip arthroplasty.

Intervention type: PROCEDURE
Intervention: hip arthroplasty
Description: resurfacing procedures (HRP), THA and Minihip-type neck-preserving total hip arthroplasty.

Intervention type: PROCEDURE
Intervention: hip arthroplasty
Description: resurfacing procedures (HRP), THA and Minihip-type neck-preserving total hip arthroplasty.
Study: NCT04823260

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotinamide Mononucleotide
Description: Nicotinamide adenine dinucleotide (NAD+) is an essential cofactor in all living cells involved in fundamental biological processes. Depletion in the levels of NAD+ is associated with traits of aging, many age-related diseases like cancer, metabolic disorders and neurological disorders. Evidence stemming from recent studies have unveiled numerous roles of NAD+ metabolism on aging and longevity and delaying the progression of age-related diseases

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotinamide Mononucleotide
Description: Nicotinamide adenine dinucleotide (NAD+) is an essential cofactor in all living cells involved in fundamental biological processes. Depletion in the levels of NAD+ is associated with traits of aging, many age-related diseases like cancer, metabolic disorders and neurological disorders. Evidence stemming from recent studies have unveiled numerous roles of NAD+ metabolism on aging and longevity and delaying the progression of age-related diseases

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotinamide Mononucleotide
Description: Nicotinamide adenine dinucleotide (NAD+) is an essential cofactor in all living cells involved in fundamental biological processes. Depletion in the levels of NAD+ is associated with traits of aging, many age-related diseases like cancer, metabolic disorders and neurological disorders. Evidence stemming from recent studies have unveiled numerous roles of NAD+ metabolism on aging and longevity and delaying the progression of age-related diseases

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Rice flour in white capsule resembling NMN

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Rice flour in white capsule resembling NMN

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Rice flour in white capsule resembling NMN
Study: NCT05254366

Intervention type: DRUG
Intervention: Remimazolam Tosilate for Injection
Description: Remimazolam Tosilate for Injection

Intervention type: DRUG
Intervention: Remimazolam Tosilate for Injection
Description: Remimazolam Tosilate for Injection
Study: NCT05763433

Intervention type: OTHER
Intervention: upper extremity bone surgery
Description: any ambulatory upper limb bone surgery carried out under axillary PNB
Study: NCT04679870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB2064
Description: GB2064 (formerly PAT-1251) is a high-affinity, selective, mechanism-based, small molecule inhibitor of LOXL2, administered twice a day
Study: NCT05057195

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Interstitial radiation therapy
Description: From 30 to 50 Gy,

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative external beam therapy
Description: 50 Gy and locally on the tumor bed up to 10-26 Gy, depending on the status of the resection margin
Study: NCT06579833

Intervention type: RADIATION
Group type: OTHER
Intervention: Histotripsy
Description: Histotripsy is a promising non-invasive technique that uses high-intensity ultrasound waves to disrupt tissue without damaging surrounding structures. It works by using high-intensity ultrasound waves to create microscopic bubbles within the tumour tissue. These bubbles rapidly expand and collapse, generating shock waves that disrupt the tissue. The technique is highly precise and can be targeted to specific areas of the liver, allowing for selective destruction of tumour cells while minimizing damage to healthy tissue.
Study: NCT04915573

Intervention type: DIAGNOSTIC_TEST
Intervention: Specimen
Description: Sputum will be collected in clean disposable containers
Study: NCT04731688

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Maintenance Group
Description: The behavioral program is rooted in social learning theory and based on our existing prenatal intervention but with full food provision to ensure gestational fat mass loss is steady and closely supervised. Brief counseling sessions are designed to review self-monitoring records, reinforce adherence to the structured food provision program, problem-solve barriers, and provide additional support. Individuals will be provided with a structured meal plan designed to promote 25% calorie restriction during the second trimester followed by eucaloric intake during the 3rd trimester. Participants will be provided three meals and two snacks on 7 days at no cost.
Study: NCT05840172

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test condom A (NRL condom with 5% benzocaine paste)
Description: In each assessment period, subjects will be provided with a condom type to use during vaginal intercourse and will report at least 4 duration records (from vaginal entry to ejaculation) over a 4-week period. Subjects will repeat the assessment period each to test all 3 condom types.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test condom B (NRL condom with 3% benzocaine paste)
Description: In each assessment period, subjects will be provided with a condom type to use during vaginal intercourse and will report at least 4 duration records (from vaginal entry to ejaculation) over a 4-week period. Subjects will repeat the assessment period each to test all 3 condom types.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Control NRL condom
Description: IIn each assessment period, subjects will be provided with a condom type to use during vaginal intercourse and will report at least 4 duration records (from vaginal entry to ejaculation) over a 4-week period. Subjects will repeat the assessment period each to test all 3 condom types.
Study: NCT06535841

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MTX-474
Description: MTX-474 is an immunoglobin G1 (IgG1) monoclonal antibody directed against Ephrin B2 that binds to and has demonstrated ability to block phosphorylation of its preferred receptor EphB4. Increased levels of circulating soluble EphrinB2 have been found in patients with systemic sclerosis.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo - Normal Saline
Study: NCT05571280

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional Supplementation
Description: The Small-quantity lipid-based nutrient supplementation (SQ-LNS) consists of micronutrients delivered in a lipid-based vehicle. All pregnant women (as of 12 weeks self-referred) within households who were randomly included in the study in the nutritional supplementation arm and their children as of 6 months of age will receive the SQ-LNS.~● Pregnant women: 20-g sachets, 20 g (1 sachet) dose per day. Nutritional composition and caloric intake.~Total = 12/13 months approximately.~● Children from 6 months of age: 20-g sachets, 20 g (1 sachet) dose per day. Nutritional composition and caloric intake. Total = 18 months.~The distribution will be made by ADECOS on a fortnightly basis.~A family ration will be distributed: family supplementation is presented in a basket of locally produced basic foods that complement the usual diet. The caloric distribution of the basket will be 45% of cereals, 30% of pulses, and 25% in oil, and 1 kg of iodized salt.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Money transfers
Description: The distribution of the amounts will be made through the corresponding financial providers, together with the Municipal or Communal Administration authorities, the Assistants of Community Activities, the Investigator's personnel, and the ADECOS. The distribution frequency will be every 3 months until the end of the study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard intervention
Description: The activities included are the following:~1. Community interventions against malnutrition and promotion of adequate nutrition: raise awareness of malnutrition and training mothers to recognize signs of malnutrition.~2. Community interventions in promoting hygiene and proper sanitation: a) Promotion of Community-Led Total Sanitation approach (CLTS)strategy: community awareness of the entire population included in the cluster about the dangers of open defecation, and the direct link to malnutrition; b) Promotion of Baby-Wash strategy: to make the community aware of the problems and consequences of unsafe water consumption.~3. Biannual supplementation with vitamin A for children from 6 to 24 months of age.~4. Biannual deworming (albendazole/mebendazole) for children from 12 months to 24 months of age and pregnant women as of 2nd quarter.~5. Malaria prophylaxis with sulfadoxine-pyrimethamine (SP) in pregnant women as of 13 weeks of pregnancy.
Study: NCT06670625

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IDAC+
Description: Diet and physical activity counselling at baseline, 6, 12 and 24 months visit.
Study: NCT06618547

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENEO 317 Model 2 excimer laser
Description: TENEO 317 Model 2 excimer laser by Transepithelial Photorefractive Keratectomy
Study: NCT05465161

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sting Mark Fiducial Marker
Description: Device insertion will occur with the designated needles and through the appropriate organ-specific route and imaging guidance. Multiple STING-MARK fiducials will be inserted. Plain film x-rays in 3 planes of the organs with the marker inserted will be taken and recorded.
Study: NCT05111561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BET Bromodomain Inhibitor ZEN-3694
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT06682520

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postpartum NEST-Rural Program (Hospital based service model)
Description: NEST-Rural services will include 3-5 nurse encounters and, if indicated, up to 3 social work encounters with mothers and their infants in the postpartum period, postpartum remote blood pressure monitoring, breastfeeding support, infant weight checks, linking mothers and infants to needed social, behavioral, and health-related resources, and integration of service delivery with healthcare providers.
Study: NCT06723366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angong Niuhuang Pill (ANP)
Description: Angong Niuhuang Pill (ANP) (3 g/pill, 1 pill/day for 5 days)

Intervention type: OTHER
Group type: OTHER
Intervention: Control (Standard treatment)
Description: Blank control
Study: NCT05227833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan fumarate (Vonaspire)
Description: Patients assigned to Vonoprazan (vonaspire) tablets will receive a daily dose of 20 mg before breakfast starting from the first day of band ligation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole 40mg
Description: Patients assigned to Pantoprazole tablets (Controloc OR Antopral OR Perloc) will receive a daily dose of 40 mg before breakfast starting from the first day of band ligation.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No Intervention
Study: NCT06732427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fospropofol Disodium for injection
Description: Group L received slow intravenous sufentanyl 0. 1 ug / kg +fospropofol Disodium for injection 8mg / kg (completed within 60 seconds)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Group B received slow intravenous sufentanyl 0. 1 ug / kg +propofol 2mg / kg (completed within 60 seconds)
Study: NCT06723262

Intervention type: OTHER
Group type: OTHER
Intervention: Tonotopic cochlear implant fitting FS4T
Description: Comparison of FS4T and FS4noT
Study: NCT06733766

Intervention type: PROCEDURE
Intervention: ultrasound-guided thermal ablation
Description: microwave ablation, radiofrequency ablation, laser ablation
Study: NCT06731894

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo urine sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo urine sample collection

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo urine sample collection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Administration
Description: Given PO

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT06732492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RD13-02 cell infusion
Description: CAR-T cells
Study: NCT06732063

Intervention type: DEVICE
Group type: OTHER
Intervention: endodontic retreatment
Description: Re-treatment of previously failed root canal treatments

Intervention type: DEVICE
Group type: OTHER
Intervention: endodontic retreatment
Description: Re-treatment of previously failed root canal treatments
Study: NCT06733896

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: trigger point pressure
Description: The midpoint of the sternocleidomastoid muscle with abundant nerve distribution and the onset and endpoint of the sternocleidomastoid muscle were used as acupoints, which can relieve localised muscle spasms and promote nerve nutrition.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: neck exercises
Description: Manual Cervical Traction Technique and others
Study: NCT06732050

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nociception guided treatment
Description: For the nociception level-guided group the same standard narcosis will be applied whilst ensuring that the NOL® level value will be maintained between 10 and 25.
Study: NCT06732518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoride Toothpaste
Description: Fluoride toothpaste containing 1000 ppm MFP and 1.5% arginine in a PCC/RNCC base

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoride free toothpaste in a chalk base
Description: Fluoride free toothpaste in a chalk base with herbal ingredients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoride free toothpaste in a PCC/RNCC base
Description: Fluoride free toothpaste in a PCC/RNCC base

Intervention type: DRUG
Group type: OTHER
Intervention: Fluoride free toothpaste in a PCC/RNCC base
Description: Fluoride free toothpaste in a PCC/RNCC base

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Toothbrush
Description: A commercially available adult soft bristle toothbrush

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Toothbrush
Description: A commercially available adult soft bristle toothbrush

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Toothbrush
Description: A commercially available adult soft bristle toothbrush

Intervention type: DEVICE
Group type: OTHER
Intervention: Toothbrush
Description: A commercially available adult soft bristle toothbrush
Study: NCT06733870

Intervention type: PROCEDURE
Group type: OTHER
Intervention: guided immediate implant surgery
Description: fully guided immediate implant placement and loading

Intervention type: PROCEDURE
Group type: OTHER
Intervention: guided immediate implant surgery
Description: fully guided immediate implant placement and loading
Study: NCT05941754

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega-3
Description: supplement in the market

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega-3
Description: supplement in the market

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: corn oil
Study: NCT06012734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LB-100
Description: IV on day 1 and day 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: IV on day 1
Study: NCT06073730

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experimental: Venetoclax in combination with Decitabine (+-sorafenib)
Description: Venetoclax (VEN) 100mg d1, 200mg d2, 400mg d3-14 Decitabine (DEC) 20mg/m2/q8h, d4-6 (infusion time \>2h) Sorafenib 600mg/d, d8-14 (FLT3/ITD mutation positive patients)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Standard dose of Venetoclax + Azacitidine
Description: Venetoclax (VEN) 100mg d1, 200mg d2, 400mg d3-28 Azacitidine (AZA) 75mg/m2/d, d3-9
Study: NCT06282679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A Injection [Botox]
Description: you are asked to return to the hospital for follow-up at weeks 2, 4, 8, and 12
Study: NCT05009342

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: below-knee soft resin cast
Description: Patients have soft resin boot between day 0 (inclusion visit) and day 21 (follow-up visit n°1)

Intervention type: DEVICE
Group type: OTHER
Intervention: Below-knee rigid resin cast
Description: Patients have rigid resin boot between day 0 (inclusion visit) and day 21 (follow-up visit n°1)
Study: NCT04245280

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.5% Injectable Solution
Description: ropivacaine 0.5% with epinephrine 2.5 mcg/ml

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: normal saline solution (NaCl 0.9%)
Study: NCT06038656

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Galactooligosaccharides (GOS)
Description: 10 g of GOS provided as 14 g of powder will be consumed after mixing it in water or yoghurt.~The absorption study test drinks administered during the 3 test conditions will be comprised as follows:~Post rest period - 50 mg of iron as ferrous fumarate (Fefum) supplement, 6 mg 54Fe as Fefum and 300 ml of water with sucrose and lactose.~Post exercise bout - 50 mg of iron as Fefum, 6 mg 58Fe as Fefum and 300 ml of water with sucrose and lactose.~Post exercise bout co-administered with GOS - 50 mg of iron as Fefum, 6 mg 57Fe as Fefum and 300 ml of water with 10 g GOS.
Study: NCT06111209

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone cypionate
Description: weekly by intramuscular injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: weekly by intramuscular injection
Study: NCT05127122

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Placebo Saline
Study: NCT06136390

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin nasal spray in combination with mindfulness based group therapy (MBGT).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo nasal spray in combination with mindfulness based group therapy (MBGT).
Study: NCT06489561

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cedrus RB-844 response pad; Adtech Behnke-Fried micro-electrodes; Neurolynx electrophysiology system
Description: Devices listed are components of a single intervention that includes: Record patient responses (Cedrus RB-844), record neuronal activity (Neurolynx) from electrodes (Adtech Behnke-Fried)
Study: NCT04912648

Intervention type: OTHER
Intervention: Longitudinal follow up
Description: Repeat follow up at 3,5 and 10 years